[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:b-cell-lymphoproliferative-disorder":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":15,"states":16},"B-Cell Lymphoproliferative Disorder",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04883437","Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",[11],"Phase 2","RECRUITING","2026-08-26T02:18:27.904411Z","2026-05-05T02:43:28.560079Z",[],[]]